HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

Table 3 Impact of HER4 expression on the overall survival (OS) and disease-free survival (DFS) in patient subcohorts stratified by treatment (TAM or AI)

Subgroup	Predictor	OS				DFS
Subgroup	Predictor	HR	95% CI		p value	HR	95% CI		p value
TAM treated	HER4 continuous	1.28	1.01	1.62	0.040	1.16	0.89	1.52	0.270
	HER4 expression (ref. no HER4 expression)	1.63	0.52	5.06	0.399	1.23	0.54	2.84	0.622
	HER4 ≥ 1 (ref. HER4 < 1)	3.22	1.17	8.86	0.024	1.36	0.63	2.97	0.436
Al treated	HER4 continuous	0.86	0.60	1.22	0.393	0.85	0.61	1.18	0.338
Al treated	HER4 expression (ref. no HER4 expression)	0.68	0.31	1.50	0.339	0.72	0.36	1.44	0.352

Significant values are shows in bold typeface
AI aromatase inhibitor, CI confidence interval, HR hazard ratio, TAM tamoxifen

ISSN: 1465-542X